At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ATHE Alterity Therapeutics Limited
Not Yet Opened 07-05 16:00:00 EDT
1.83
+0.01
+0.68%
盘后1.83
+0.00+0.14%
18:45 EDT
High1.84
Low1.80
Vol5.11K
Open1.83
D1 Closing1.82
Amplitude2.20%
Mkt Cap15.97M
Tradable Cap14.49M
Total Shares8.74M
T/O9.32K
T/O Rate0.06%
Tradable Shares7.93M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Alterity Therapeutics to Present at the MST Access ‘Hidden Gems in Life Sciences’ Webinar
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.